GOVERNMENT OF INDIA MINISTRY OF CHEMICALS & FERTILIZERS DEPARTMENT OF PHARMACEUTICALS

LOK SABHA

UNSTARRED QUESTION NO. 447

TO BE ANSWERED ON 1st DECEMBER, 2015

NPPAI AND JAN AUSHADHI STORE

447. SHRI B. SENGUTTUVAN:

Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

- (a) whether the National Pharmaceutical Pricing Authority of India (NPPAI) has capped the maximum retail sale price of Jan Aushadhi Drugs used in the treatment of diabetes, tuberculosis and malaria etc.;
- (b) would the Ministry be please to furnish the number of the drugs, the prices of which the NPPAI has the authority to control;
- (c) whether the NPPAI has authority to control the prices of generic drugs, if so, how does it affect control of the prices; and
- (d) whether the Ministry takes adequate steps to ensure that the controlled-drug manufacturers do not stop the manufacture of the controlled-drugs, if so, the details thereof?

ANSWER

MINISTER OF STATE IN THE MINISTRY OF CHEMICALS & FERTILIZERS (SHRI HANSRAJ GANGARAM AHIR)

- (a): Ceiling prices fixed by National Pharmaceutical Pricing Authority (NPPA) under the provisions of Drugs (Prices Control) Order, 2013 (DPCO, 2013) including the drugs used in treatment of diabetes, tuberculosis and malaria are applicable for Jan Aushadhi medicines also.
- (b), (c) & (d): All the medicines specified in the National List of Essential Medicines 2011 (NLEM) which contains 680 medicines (628 net medicines) have been included in the First Schedule of DPCO, 2013, notified on 15.05.2013, and brought under price control. Prices of medicines are fixed by NPPA as per the provisions of DPCO, 2013 and are applicable to generic medicines also.

Paragraph 21(2) of the DPCO, 2013 provides that any manufacturer of scheduled formulation, intending to discontinue any scheduled formulation from the market shall issue a public notice and also intimate the Government in Form-IV of DPCO, 2013 at least six months prior to the intended date of discontinuation and the Government may, in public interest, direct the manufacturer of the scheduled formulation to continue with required level of production or import for a period not exceeding one year, from the intended date of such discontinuation within a period of sixty days of receipt of such intimation.
